title: [Prevention of gram-negative and gram-positive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].
abstract: Three immunoglobulin preparations for intravenous infusion were compared in vivo to determine their relative protective capacity against several gram-negative and gram-positive pathogens. Polyglobin N is a conventional IgG concentrate. Psomaglobin N is identical in formulation to Polyglobin N but is prepared from the plasma of donors who have naturally high levels of antibody to lipopolysaccharide antigens of Pseudomonas aeruginosa. IgGMA is a conventional IgG concentrate containing 12% IgG and 16% IgA. In a murine model of burn wound sepsis the three IgG preparations were similarly protective against three or ten strains of P. aeruginosa. Psomaglobin N and Polyglobin N were significantly (p less than or equal to 0.015) more protective than IgGMA against six of ten and three of ten strains of P. aeruginosa, respectively. In a murine model of Streptococcus pneumoniae type 3 pneumonia, the three Ig preparations were similarly protective. IgGMA was significantly more protective (p less than or equal to 0.025) than Psomaglobin N and Polyglobin N against Salmonella typhimurium in murine peritonitis. However, the mean protective dose (PD50) of the two later preparations was less than or equal to 20 mg/kg body weight. In models of peritonitis both Psomaglobin N and Polyglobin N were more protective than IgGMA (p less than or equal to 0.004) against Haemophilus influenzae b, Klebsiella pneumoniae, Serratia marcescens 06:H3 and group B Streptococcus types 1b and 1c. Psomaglobin N and ciprofloxacin were employed to treat established polymicrobial murine burn wound sepsis resulting from contamination of the burn site with mixtures of P. aeruginosa and Staphylococcus aureus.(ABSTRACT TRUNCATED AT 250 WORDS)
mesh_terms: D000818:Animals; D001424:Bacterial Infections / Q000628:therapy*; D002056:Burns / Q000628:therapy*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D007074:Immunoglobulin G / Q000627:therapeutic use*; D051379:Mice; D008815:Mice, Inbred Strains; D011552:Pseudomonas Infections / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D013203:Staphylococcal Infections / Q000628:therapy; D013290:Streptococcal Infections / Q000628:therapy; D014946:Wound Infection / Q000628:therapy*
chemical_list: D007074:Immunoglobulin G; D002939:Ciprofloxacin
vernacular_title: Prophylaxe gramnegativer und grampositiver Infektionen mit drei intravenösen Immunglobulin-Präparaten und Therapie der experimentellen polymikrobiellen Verbrennungssepsis mit intravenösem Pseudomonas-Immunglobulin G und Ciprofloxacin im Tiermodell.